報價延遲最少15分鐘:2026/05/22 04:21 EDT
盤前時段
|
||||
|
0.935 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.935
|
|
|
| 價值評估 |
|
盈利(現時/預測)
--/-1.10
|
|
企業價值
5.67M
|
| 資產負債 |
|
每股賬面淨值
0.82
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
286.00K
|
|
每股收益
6.89
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107. |
